Active Clinical Trials
Numerous clinical trials are always active (i.e., open and enrolling patients) in the ECOG-ACRIN Cancer Research Group, which focuses its research on adults who have or are at risk of developing cancer. This section of the website contains a searchable list of all active trials. On the table below, hover over any of the column headings and click the up/down arrows to sort. You can also search by keyword. To access more information about a particular trial, click on the trial ID.
| Cancer Type | Trial ID/More Info | Target Patient Population | Study Type | ECOG-ACRIN Oversight Committee(s) |
|---|---|---|---|---|
| Various | EAQ202 | Ages 18-39 with any type of cancer except basal cell carcinoma | Observation (Patient Reporting) | Health Equity; Adolescent and Young Adult Oncology |
| Various | EAQ222CD / CostCOM | Ages 18+ with any type of solid cancer of any stage | Intervention | Cancer Care Delivery Research |
| Various | EAY191 / ComboMATCH | Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or other places in the body (advanced) | Patient Registration | Developmental Therapeutics |
| Various | EAY191-E5/ ComboMATCH-E5 | Metastatic (advanced) solid tumorsĀ with a KRAS G12C mutation | Treatment | Developmental Therapeutics |
| Bladder | EA8212 / BRIDGE | High risk; has not spread to the muscleĀ | Treatment | Genitourinary |
| Blood | EA4231 | Non-Hodgkin lymphoma (diffuse large B-cell) | Treatment | Lymphoma |
| Blood | EA9181 | Acute lymphoblastic leukemia (ALL) | Treatment | Leukemia |
| Blood | EA9213 | Acute lymphoblastic leukemia (ALL), T-cell Type | Treatment | Leukemia |
| Blood | EAA173 / DETER-SMM | Smoldering myeloma | Treatment | Myeloma |
| Blood | EAA181 / EQUATE | Myeloma, newly diagnosed | Treatment | Myeloma |
| Blood | EAQ211 | Survivors of Hodgkin or Non-Hodgkin lymphoma, age 15-39 when diagnosed | Observation | Health Equity; Adolescent and Young Adult Oncology |
| Blood | Acute myeloid leukemia (AML) | Treatment | Leukemia | |
| Brain | Glioblastoma, newly diagnosed | Imaging | Brain Cancer Working Group | |
| Breast | EA1211 / DIRECT | Early stage, HER2 positive type | Imaging | Breast |
| Breast | EAQ221CD / CONCURxP | Metastatic (advanced) | Intervention | Cancer Care Delivery Research |
| Colorectal | EA2222 / PUMP | Metastatic (advanced to the liver), not able to be removed by surgery (inoperable) | Treatment | Gastrointestinal |
| Esophagus | EA2174 | Locally advanced, able to be removed by surgery (operable) | Treatment | Gastrointestinal |
| Esophagus and Stomach | EA2183 | Metastatic (advanced), HER2 negative type | Treatment | Gastrointestinal |
| Gallbladder | EA2197 / OPT-IN | Discovered at time of surgery to remove the gallbladder | Treatment | Gastrointestinal |
| Head and Neck | EA3132 | p53-mutated squamous cell type, after surgery | Treatment | Head and Neck |
| Head and Neck | EA3191 | Squamous cell carcinoma of the head and neck that has come back after initial therapy | Treatment | Head and Neck |
| Head and Neck | EA3202 | Metastatic (advanced) squamous cell type that has returned after treatment with immune checkpoint inhibitors | Treatment | Head and Neck |
| Head and Neck | EA3211 | Metastatic (advanced) squamous cell carcinoma | Treatment | Head and Neck |
| Kidney | EA8211 / SOAR | Metastatic (advanced) renal cell carcinoma | Treatment | Genitourinary |
| Lung | EA5162 | Non-small cell type, metastatic (advanced) | Treatment | Thoracic |
| Lung | EA5182 | Non-small cell type, metastatic (advanced) | Treatment | Thoracic |
| Lung | EA5221 / ACHIEVE | Non-small cell type, metastatic (advanced) in older patients aged 70+ | Treatment | Thoracic; Geriatric Oncology |
| Lung | PrE1702 | Non-small cell type, with EGFR mutation, metastatic (advanced) | Observational | Thoracic |
| Melanoma (Skin) | EA6141 | Metastatic (advanced) | Treatment | Melanoma |
| Melanoma (Skin) | EA6192 / PET-Stop | Metastatic (advanced) | Treatment | Melanoma |
| Melanoma (Skin) | EA6194 | Able to be removed by surgery (operable) | Treatment | Melanoma |
| Pancreas | EA2185 | Patients with non-cancerous pancreas cysts | Screening/Early Detection | Gastrointestinal |
| Pancreas | EA2192 / APOLLO | Has been surgically removed and has a BRCA1, BRCA2, or PALB2 mutation | Treatment | Gastrointestinal |
| Penis | EA8134 / InPACT | Spread to nearby tissue or lymph nodes (locally advanced) | Treatment | Genitourinary |
| Prostate | EA8171 | Newly diagnosed, before surgery | Imaging/Treatment Planning | Genitourinary |
| Prostate | EA8184 | On close monitoring; at low risk of progressing | Prevention | Genitourinary |
| Prostate | EA8191 / INDICATE | Has come back after surgery | Treatment | Genitourinary |
| Rectum | EA2201 | Locally advanced, MSI-H or dMMR type | Treatment | Gastrointestinal |
| Sarcoma (Soft Tissue Cancer) | EA7211 / STRASS 2 | Able to be removed by surgery (operable); at high risk of returning | Treatment | Sarcoma |
| Sarcoma (Soft Tissue/Bone Cancer) | EA7222 | Metastatic (advanced), not able to be removed by surgery | Treatment | Sarcoma |
| Throat | EA3161 | HPV positive type | Treatment | Head and Neck |
| Thyroid | EA3231 | Differentiated and BRAF V600E-mutated type that has spread after standard treatment | Treatment | Head and Neck |
| Upper Urinary Tract | EA8192 | High grade (aggressive) | Treatment | Genitourinary |